{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:58Z","timestamp":1792788358646,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"People\u2019s Livelihood Science and Technology Special Projects of the Key Research and Development Plan from the Science and Technology Department of Hebei Province","award":["20377757D"],"award-info":[{"award-number":["20377757D"]}],"id":[{"id":"https:\/\/ror.org\/00tbh0t11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"DOI":"10.1245\/s10434-026-20601-8","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:08:11Z","timestamp":1790266091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-progression Surgery Added to Imatinib is Associated with Prolonged Survival in Oligometastatic GIST: A Covariate-Matched Study"],"prefix":"10.1245","author":[{"given":"Mingfeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7903-362X","authenticated-orcid":false,"given":"Xinran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"1","key":"20601_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","volume":"7","author":"JY Blay","year":"2021","unstructured":"Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021;7(1):22.","journal-title":"Nat Rev Dis Primers."},{"issue":"3","key":"20601_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11523-023-00960-y","volume":"18","author":"M Mohammadi","year":"2023","unstructured":"Mohammadi M, IJzerman NS, Hollander D, et al. Improved efficacy of first-line imatinib in advanced gastrointestinal stromal tumors (GIST): The Dutch GIST Registry Data. Target Oncol. 2023;18(3):415\u201323.","journal-title":"Target. Oncol."},{"issue":"11","key":"20601_CR3","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.18632\/oncotarget.3455","volume":"6","author":"DK Reyes","year":"2015","unstructured":"Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6(11):8491\u2013524.","journal-title":"Oncotarget."},{"issue":"10","key":"20601_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/0284186X.2017.1330555","volume":"56","author":"I Hompland","year":"2017","unstructured":"Hompland I, Bruland \u00d8S, Sundby Hall K, et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncol. 2017;56(10):1317\u201323.","journal-title":"Acta Oncol."},{"issue":"3","key":"20601_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar. Behav Res."},{"issue":"7447","key":"20601_CR6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/bmj.328.7447.1073","volume":"328","author":"JM Bland","year":"2004","unstructured":"Bland JM, Altman DG. The logrank test. BMJ. 2004;328(7447):1073.","journal-title":"BMJ."},{"issue":"6","key":"20601_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710\u20138.","journal-title":"Am J Epidemiol."},{"issue":"2","key":"20601_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ijc.21164","volume":"117","author":"S Bauer","year":"2005","unstructured":"Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005;117(2):316\u201325.","journal-title":"Int J Cancer."},{"issue":"13","key":"20601_CR9","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1245\/s10434-014-3866-4","volume":"21","author":"SJ Park","year":"2014","unstructured":"Park SJ, Ryu MH, Ryoo BY, et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann Surg Oncol. 2014;21(13):4211\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20601_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00423-023-03052-7","volume":"408","author":"A Rahimi-Ardabily","year":"2023","unstructured":"Rahimi-Ardabily A, Alshehri A, Alharbi A, et al. Liver resection for metastatic GIST tumor improves survival in the era of tyrosine kinase inhibitors: a systematic review and meta-analysis. Langenbecks Arch Surg. 2023;408(1):373.","journal-title":"Langenbecks Arch Surg."},{"issue":"8","key":"20601_CR11","first-page":"1187","volume":"42","author":"MFJ Seesing","year":"2016","unstructured":"Seesing MFJ, Tielen R, van Hillegersberg R, et al. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. Eur J Surg Oncol. 2016;42(8):1187\u201393.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"20601_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/SLA.0000000000002281","volume":"268","author":"M Fairweather","year":"2018","unstructured":"Fairweather M, Gonzalez RJ, Strauss D, et al. Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors: a 2-institutional analysis. Ann Surg. 2018;268(2):296\u2013302.","journal-title":"Ann Surg."},{"issue":"18 Pt 1","key":"20601_CR13","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.1158\/1078-0432.CCR-06-0858","volume":"13","author":"J Desai","year":"2007","unstructured":"Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007;13(18 Pt 1):5398\u2013405.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"20601_CR14","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12(6):1743\u20139.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"20601_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378\u201382.","journal-title":"Nat Rev Clin Oncol."},{"issue":"6","key":"20601_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hern\u00e1n MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656\u201364.","journal-title":"Am J Epidemiol."},{"key":"20601_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.","journal-title":"BMC Med Res Methodol."},{"issue":"3","key":"20601_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10120-007-0425-8","volume":"10","author":"SE Al-Batran","year":"2007","unstructured":"Al-Batran SE, Hartmann JT, Heidel F, et al. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer. 2007;10(3):145\u201352.","journal-title":"Gastric Cancer."},{"key":"20601_CR19","doi-asserted-by":"crossref","first-page":"108446","DOI":"10.1016\/j.pharmthera.2023.108446","volume":"247","author":"A Di Vito","year":"2023","unstructured":"Di Vito A, De Luca I, Granieri L, et al. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): a lesson from ripretinib. Pharmacol Ther. 2023;247:108446.","journal-title":"Pharmacol Ther."},{"key":"20601_CR20","doi-asserted-by":"publisher","first-page":"115473","DOI":"10.1016\/j.ejca.2025.115473","volume":"222","author":"N Penel","year":"2025","unstructured":"Penel N, Le Cesne A, Blay JY. Adjuvant treatment of gastrointestinal stromal tumor: state of the art in 2025. Eur J Cancer. 2025;222:115473.","journal-title":"Eur J Cancer."},{"key":"20601_CR21","volume-title":"Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of common malignant tumors 2025","author":"Y Ye","year":"2025","unstructured":"Ye Y, et al. Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of gastrointestinal stromal tumor 2025. In: J Yu, J Li, J Ma, et al., editors. Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of common malignant tumors 2025. Beijing: People\u2018s Medical Publishing House; 2025."},{"issue":"12","key":"20601_CR22","doi-asserted-by":"publisher","first-page":"e184060","DOI":"10.1001\/jamaoncol.2018.4060","volume":"4","author":"CP Raut","year":"2018","unstructured":"Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4(12):e184060.","journal-title":"JAMA Oncol."},{"issue":"6","key":"20601_CR23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/SLA.0000000000003988","volume":"272","author":"RP DeMatteo","year":"2020","unstructured":"DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2020;272(6):935\u201341.","journal-title":"Ann Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20601-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:08:12Z","timestamp":1790266092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20601-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":23,"alternative-id":["20601"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20601-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University in accordance with the Declaration of Helsinki (REC number: 2021KS017).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}